{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["289"],"submitter":["Choudhary S"],"funding":["Indian Council of Medical Research (ICMR), New Delhi"],"pubmed_abstract":["The rapid emergence of novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), originated from Wuhan, China, imposed a global health emergency. Angiotensin-converting enzyme 2 (ACE2) receptor serves as an entry point for this deadly virus while the proteases like furin, transmembrane protease serine 2 (TMPRSS2) and 3 chymotrypsin-like protease (3CLpro) are involved in the further processing and replication of SARS-CoV-2. The interaction of SP with ACE2 and these proteases results in the SARS-CoV-2 invasion and fast epidemic spread. The small molecular inhibitors are reported to limit the interaction of SP with ACE2 and other proteases. Arbidol, a membrane fusion inhibitor approved for influenza virus is currently undergoing clinical trials against COVID-19. In this context, we report some anal"],"journal":["Virus research"],"pagination":["198146"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7455547"],"repository":["biostudies-literature"],"pubmed_title":["Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19."],"pmcid":["PMC7455547"],"pubmed_authors":["Choudhary S","Silakari O"],"additional_accession":[]},"is_claimable":false,"name":"Scaffold morphing of arbidol (umifenovir) in search of multi-targeting therapy halting the interaction of SARS-CoV-2 with ACE2 and other proteases involved in COVID-19.","description":"The rapid emergence of novel coronavirus, SARS-coronavirus 2 (SARS-CoV-2), originated from Wuhan, China, imposed a global health emergency. Angiotensin-converting enzyme 2 (ACE2) receptor serves as an entry point for this deadly virus while the proteases like furin, transmembrane protease serine 2 (TMPRSS2) and 3 chymotrypsin-like protease (3CLpro) are involved in the further processing and replication of SARS-CoV-2. The interaction of SP with ACE2 and these proteases results in the SARS-CoV-2 invasion and fast epidemic spread. The small molecular inhibitors are reported to limit the interaction of SP with ACE2 and other proteases. Arbidol, a membrane fusion inhibitor approved for influenza virus is currently undergoing clinical trials against COVID-19. In this context, we report some anal","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2026-04-07T21:39:23.551Z","creation":"2020-09-04T07:06:44Z"},"accession":"S-EPMC7455547","cross_references":{"pubmed":["32866534"],"doi":["10.1016/j.virusres.2020.198146"]}}